Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2004

Kurzrock Razelle, Albitar Maher, Cortes Jorge E, Estey Elihu H, Faderl Stefan H, Garcia-Manero Guillermo, Thomas Deborah A, Giles Francis J, Ryback Mary Ellen, Thibault Alain, De Porre P, Kantarjian Hagop M

Abstract excerpt

PURPOSE: To perform a phase II study of the farnesyl transferase inhibitor R115777 (Zarnestra; Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ) in patients with myelodysplastic syndrome (MDS), using doses recommended in a phase I study in relapsed/refractory leukemia. PAT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkyl and Aryl Transferases
Share to Farnesyltranstransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feasibility Studies

Share to Fibroblast Growth Factor 2

Share to Maximum Tolerated Dose

Share to Myelodysplastic Syndromes

Share to Quinolones

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 15051776
DOI: 10.1200/JCO.2004.08.082

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15051776-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.PMID 15051776Read ↗

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.Semantic proximity Read ↗

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndromeSemantic proximity Read ↗

A Phase I Study of MLN4924 and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeSemantic proximity Read ↗

Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.Semantic proximity Read ↗

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.Semantic proximity Read ↗

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.Semantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Established and emerging targeted therapies in the myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.